Royalty Pharma plc Increase (Decrease) in Other Current Liabilities
Royalty Pharma plc (RPRX) reported Increase (Decrease) in Other Current Liabilities of $14.26 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherCurrentLiabilities · last filed 2026-08-05
- Royalty Pharma plc increase (decrease) in other current liabilities for the quarter ending 2026-06-30 was -$31.00K.
- Royalty Pharma plc increase (decrease) in other current liabilities for the quarter ending 2026-03-31 was $14.29M.
- Royalty Pharma plc increase (decrease) in other current liabilities for the quarter ending 2025-12-31 was -$1.01M.
- Royalty Pharma plc increase (decrease) in other current liabilities for the quarter ending 2025-09-30 was -$1.34M.
- Royalty Pharma plc increase (decrease) in other current liabilities for fiscal 2025 was -$2.35M.
- Royalty Pharma plc increase (decrease) in other current liabilities for fiscal 2024 was $0.00.
- Royalty Pharma plc increase (decrease) in other current liabilities for fiscal 2023 was $0.00.
| Period end | Increase (Decrease) in Other Current Liabilities 3 month | Increase (Decrease) in Other Current Liabilities 6 month | Increase (Decrease) in Other Current Liabilities 6 month as first filed | Increase (Decrease) in Other Current Liabilities 9 month | Increase (Decrease) in Other Current Liabilities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$31.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $14.26M 10-Q · filed 2026-08-05 | $13.25M derived: sum of 3 quarters · filed 2026-08-05 | $11.91M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $14.29M 10-Q · filed 2026-05-06 | $13.28M derived: sum of 2 quarters · filed 2026-05-06 | $11.94M derived: sum of 3 quarters · filed 2026-05-06 | $11.94M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | -$1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$2.35M derived: sum of 2 quarters · filed 2026-02-11 | -$2.35M derived: sum of 3 quarters · filed 2026-08-05 | -$2.35M 10-K · filed 2026-02-11 | |
| 2025-09-30 | -$1.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$1.34M derived: sum of 2 quarters · filed 2026-08-05 | -$1.34M 10-Q · filed 2025-11-05 | -$2.32M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 | -$332.00K 10-Q · filed 2025-08-06 | -$980.00K derived: sum of 3 quarters · filed 2026-08-05 | -$5.04M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-06 | -$980.00K derived: sum of 2 quarters · filed 2026-05-06 | -$5.04M derived: sum of 3 quarters · filed 2026-05-06 | ||
| 2024-12-31 | -$980.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$5.04M derived: sum of 2 quarters · filed 2026-02-11 | $0.00 10-K · filed 2026-02-11 | ||
| 2024-09-30 | -$4.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $980.00K 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | $5.04M 10-Q · filed 2025-08-06 | ||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $0.00 derived: sum of 2 quarters · filed 2026-02-11 | $0.00 10-K · filed 2026-02-11 | ||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 | ||||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-04 | ||||
| 2021-06-30 | $2.73M 10-Q · filed 2022-08-04 | ||||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |